Jason R. Kelly - Mar 14, 2023 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: CEO & Founder, Director
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Mar 14, 2023
Transactions value $: -$399,000
Form type: 4
Date filed: 3/16/2023, 05:29 PM
Previous filing: Mar 3, 2023
Next filing: Mar 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Sale	-$399K	-300K	-2.38%	$1.33	12.3M	Mar 14, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.290 to $1.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Content

The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.290 to $1.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

CEO & Founder